DOK3 promotes atopic dermatitis by enabling the phosphatase PP4C to inhibit the T cell signaling mediator CARD11.

Sci Signal

Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Republic of Singapore.

Published: October 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The scaffolding protein CARD11 is a critical mediator of antigen receptor signaling in lymphocytes. Hypomorphic (partial loss-of-function) mutations in CARD11 are associated with the development of severe atopic dermatitis, in which T cell receptor signaling is reduced and helper T cell differentiation is skewed to an allergy-associated type 2 phenotype. Here, we found that the docking protein DOK3 plays a key role in the pathogenesis of atopic dermatitis by suppressing CARD11 activity. DOK3 interacted with CARD11 and decreased its phosphorylation in T cells by recruiting the catalytic subunit of protein phosphatase 4, thereby dampening downstream signaling. Knocking out enhanced the production of the cytokine IFN-γ by T cells, which conferred protection against experimental atopic dermatitis-like skin inflammation in mice. The expression of was increased in T cells isolated from patients with atopic dermatitis and inversely correlated with expression. A subset of hypomorphic CARD11 variants found in patients with atopic dermatitis bound more strongly than wild-type CARD11 to DOK3. Our findings suggest that the strength of the interaction of DOK3 with CARD11 may predispose individuals to developing atopic dermatitis.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.adg5171DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
24
card11
8
receptor signaling
8
patients atopic
8
atopic
7
dermatitis
6
dok3
5
dok3 promotes
4
promotes atopic
4
dermatitis enabling
4

Similar Publications

Galectins in Inflammatory Skin Diseases: Mechanisms and Therapeutic Potential.

J Invest Dermatol

September 2025

Department of Dermatology, Keck School of Medicine of University of South California, Los Angeles, California, USA; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Electronic address:

This review examines the roles of galectins, a family of animal lectins, in inflammatory skin diseases, focusing on their involvement in the pathogenesis of psoriasis, atopic dermatitis, contact dermatitis, and common autoimmune diseases. We highlight the differential expression of galectins in lesional skin and their correlation with inflammatory mediators. In addition, we summarize the functions and mechanisms of action of endogenous galectins, as revealed through studies of genetically engineered cell lines and experimental animals.

View Article and Find Full Text PDF

Methods to Validate Digital Health Technologies for Dermatology.

J Invest Dermatol

September 2025

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Sibel Health, Chicago, Illinois, USA; Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois, USA. Electronic address:

The integration of wearable medical devices and digital health technologies (DHTs) in health care has grown significantly during the past 2 decades, particularly in dermatology, in which objective measurement of symptoms such as itch remains challenging. This review examines the evolution of DHTs in dermatology, focusing on the validation frameworks necessary for their implementation in clinical trials and research. We discuss the key stages of validation: hardware validation to ensure device reliability, analytical validation to transform raw sensor data into meaningful metrics, and clinical validation to demonstrate utility in specific patient populations.

View Article and Find Full Text PDF

Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.

View Article and Find Full Text PDF